Use of S-nitrosothiol signaling to treat disordered control of breathing
View Patent ↗The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in FIG. 1 C the ability of endogenous SNO g to increase V E in freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in V E , whereas D-CSNO had no effect (left bar graph is the equivalent increases in V E , whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).
1. A method of increasing minute ventilation (V E ) at the level of the brainstem respiratory control centers in the nucleus tractus solitarius of an individual, said method comprising the step of administering to said individual a composition comprising an S-nitrosylating agent, wherein the S-nitrosylating agent is selected from the group consisting of ethyl nitrite, glutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine, and S-nitroso-N-acetyl cysteine.
2. The method of claim 1 wherein the S-nitrosylating agent is N-acetyl cysteine, and the composition is administered by inhalation.
3. The method of claim 1 wherein the S-nitrosylating agent is N-acetyl cysteine and the composition is administered orally.
4. The method of claim 1 wherein the S-nitrosylating agent is S-nitroso-N-acetyl cysteine, and the composition is administered by inhalation.
5. The method of claim 1 wherein the S-nitrosylating agent is S-nitroso-N-acetyl cysteine, and the composition is administered orally.